VEGFA Upregulates FLJ10540 Found at: doi:10.1371/journal.pone.0005052.s003 (8.56 MB TIF) Author Contributions Acknowledgments It is acknowledge that the technical services provided by Microarray and Gene Expression Analysis Core Facility of the National Yang-Ming University VGH Genome Research Center (VYMGC). References 1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108. 2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71–96. 3. GA KBaP (2008) Surgical management of non-small cell lung cancer. Pearson’s Thoracic & Esophageal Surgery. Philadelphia, PA: Churchill Livingstone/ Elsevier. pp 765–780. 4. Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362–374. 5. Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor RE (1996) Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 15: 507–525. 6. Alitalo K, Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1: 219–227. 7. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423–436. 8. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, et al. (2001) Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7: 3410–3415. 9. Fabbro M, Zhou BB, Takahashi M, Sarcevic B, Lal P, et al. (2005) Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev Cell 9: 477–488. 10. Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, et al. (2006) Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene 25: 480–486. 11. Zhao WM, Seki A, Fang G (2006) Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis. Mol Biol Cell 17: 3881–3896. 12. Martinez-Garay I, Rustom A, Gerdes HH, Kutsche K (2006) The novel centrosomal associated protein CEP55 is present in the spindle midzone and the midbody. Genomics 87: 243–253. 13. Chen CH, Lu PJ, Chen YC, Fu SL, Wu KJ, et al. (2007) FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene 26: 4272–4283. 14. Yoeli-Lerner M, Toker A (2006) Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5: 603–605. 15. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655–1657. 16. Bouwknecht JA, Paylor R (2002) Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behav Brain Res 136: 489–501. 17. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70. 18. Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667–676. 19. Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM, et al. (2004) Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther 9: 510–518. 20. Kim D, Kim S, Koh H, Yoon SO, Chung AS, et al. (2001) Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15: 1953–1962. 21. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, et al. (2005) Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20: 539–550. 22. Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR (2001) AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61: 589–593. 23. Shih JY, Yang SC, Hong TM, Yuan A, Chen JJ, et al. (2001) Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst 93: 1392–1400. 24. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, et al. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66: 1354–1362. 25. Kim SA, Kim HW, Kim DK, Kim SG, Park JC, et al. (2006) Rapid induction of malignant tumor in Sprague-Dawley rats by injection of RK3E-ras cells. Cancer Lett 235: 53–59. 26. Li X, Deng W, Nail CD, Bailey SK, Kraus MH, et al. (2006) Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. Oncogene 25: 609–621. 27. Niehrs C, Pollet N (1999) Synexpression groups in eukaryotes. Nature 402: 483–487. Conceived and designed the experiments: CHC JML TYC JWP YCW CYH. Performed the experiments: CHC CYC TSC. Analyzed the data: CHC TYC LJS YCL. Contributed reagents/materials/analysis tools: YRH CKC. Wrote the paper: CHC CYH. Checked and proofed the paper: YRH CKC. 28. Zachary I (2003) VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 31: 1171–1177. 29. Laramee M, Chabot C, Cloutier M, Stenne R, Holgado-Madruga M, et al. (2007) The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. J Biol Chem 282: 7758–7769. 30. Shibusa T, Shijubo N, Abe S (1998) Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4: 1483–1487. 31. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, et al. (1999) Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160: 1269–1273. 32. Lantuejoul S, Constantin B, Drabkin H, Brambilla C, Roche J, et al. (2003) Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 200: 336–347. 33. Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, et al. (2002) A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 86: 558–563. 34. Volm M, Koomagi R, Mattern J (1997) Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74: 64–68. 35. Ohta Y, Watanabe Y, Murakami S, Oda M, Hayashi Y, et al. (1997) Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer 76: 1041–1045. 36. Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 39 kinase/AKT pathways. Oncogene 24: 7443–7454. 37. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, et al. (2006) Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66: 46–51. 38. Dance M, Montagner A, Yart A, Masri B, Audigier Y, et al. (2006) The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase. J Biol Chem 281: 23285–23295. 39. Abid MR, Guo S, Minami T, Spokes KC, Ueki K, et al. (2004) Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol 24: 294–300. 40. Kroll J, Waltenberger J (1997) The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272: 32521–32527. 41. Thakker GD, Hajjar DP, Muller WA, Rosengart TK (1999) The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 274: 10002–10007. 42. Marinov M, Fischer B, Arcaro A (2007) Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 63: 172–182. 43. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A, et al. (2001) Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 386: 293–301. 44. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, et al. (2004) Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 170: 1088–1094. 45. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, et al. (2006) Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24: 306–314. 46. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, et al. (2003) Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12: 660–664. 47. David O, Jett J, LeBeau H, Dy G, Hughes J, et al. (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage- independent survival disadvantage. Clin Cancer Res 10: 6865–6871. 48. Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986–3997. 49. Gupta AK, Soto DE, Feldman MD, Goldsmith JD, Mick R, et al. (2004) Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 182: 151–162. 50. Su Z, Honek JF (2007) Emerging bacterial enzyme targets. Curr Opin Investig Drugs 8: 140–149. PLoS ONE | www.plosone.org 12 April 2009 | Volume 4 | Issue 4 | e5052